Floatz Rating
B61/100
Confidence
Indicative
Sponsor
Roswell Park Cancer Institute
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06733350CT.gov Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance | — | Recruiting | — | — | — |
NCT06084338CT.gov Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc | — | Recruiting | — | — | — |
NCT06059118CT.gov Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT05773183CT.gov Exploring the Relationship Between Androgen Metabolism, Metabolic Disease and Skeletal Muscle Energy Balance in Men | — | Unknown | — | — | — |
NCT05081193CT.gov Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer | — | Completed | — | — | — |
NCT04134130CT.gov The Role of Follicle Stimulating Hormone in Advanced Prostate Cancer | — | Completed | — | — | — |
NCT03734653CT.gov Testosterone Therapy in Castration Resistant Prostate Cancer | — | Completed | — | — | — |
NCT01084759CT.gov A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer | — | Completed | — | — | — |
NCT00577980CT.gov Testosterone in Castration-Resistant Prostate Cancer | — | Withdrawn | — | — | — |
NCT00515112CT.gov Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer | — | Terminated | — | — | — |
Show 2 more trialsShow fewer
NCT00587431CT.gov Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer | — | Completed | — | — | — |
NCT00006044CT.gov Testosterone in Treating Patients With Progressive Prostate Cancer That No Longer Responds to Hormone Therapy | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Testosterone Undecylate (this asset) | Roswell Park Cancer Institute | Approved | B · 61 |
| Avodart | Bay State Clinical Trials, Inc. | P4 | BBB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Propofol | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Degarelix | Bayer | P4 | BBB |
| Flotufolastat F 18 | Washington University School of Medicine | P4 | BB |
| AVOLVE | Masonic Cancer Center, University of Minnesota | P4 | BB |
| Estramustine | The University of Texas Health Science Center, Houston | P3 | BB |
| Pasireotide | RECORDATI GROUP | P4 | BB |
+42 more in the Prostate Cancer cohort
Other indications for Testosterone Undecylate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hypogonadotropic Hypogonadism | — | P4 | A · 82 |
| Type 2 Diabetes Mellitus | — | P4 | BBB · 73 |
| Sexual Disorder | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Testosterone Undecylate in Prostate Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/testosterone-undecylate-prostate-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →